



# 13/fwt  
12-06-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

NOV 26 2002

In re PATENT APPLICATION OF

Papadopoulos et al.

Application No. 09/762,594

Filed: June 22, 2001

Title: Peripheral-Type Benzodiazepine Receptor Associated Proteins, Cloning, Expression and Methods of use

TECH CENTER 1600/2900  
Group Art Unit: 1647

Examiner: B. Bunner

November 21, 2002


ELECTION/RESTRICTION RESPONSE

Hon. Commissioner of Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action [Restriction Requirement] mailed on August 22, 2002, Applicants elect without traverse Group I, claims 1-17 and 34-35, drawn to an isolated PBR-associated protein DNA fragment, a recombinant DNA construct, host cell, and a method for producing PAP peptide.

If the examiner has any questions relating to this application, he is respectfully requested to contact the undersigned at the telephone number given below.

By:   
Robin L. Teskin  
Registration No. 35,030

1600 Tysons Boulevard  
McLean, VA 22102  
(703) 905-2200  
(703) 905-2500 Facsimile

11/22/2002 NM0HAMM1 00000150 09762594

01 FC:2252

200.00 CH

30334413V1

Attorney Docket 076934-0277848

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

PATENT APPLICATION

NOV 26 2002

Inventor(s): Papadopoulos et al.

Appln. No.: 09 762,594

Series Code ↑

Serial No. ↑

Filed: June 22, 2001

Hon. Commissioner of Patents  
Washington, D.C. 20231

Sir:

REPLY/AMENDMENT/LETTER

Group Art Unit 1647

Examiner: B. Bunner


Atty. Dkt. P 0277848

M#

Client Ref

Appln. Title: Peripheral-type Benzodiazepine  
Receptor Associated Protein, Cloning,  
Expression and Methods of Use

TECH CENTER 1600/2900



Date: November 21, 2002

#12/12  
12-0602

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim	For B & C See Required Separate Paper (Pat-256)				
A. <input type="checkbox"/> NOT made B. <input type="checkbox"/> Withdrawn C. <input type="checkbox"/> made herewith D. <input checked="" type="checkbox"/> made previously					

	Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	**minus	0	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	***minus	0	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application) .....	add		+ \$280/\$140 =	+ \$0		104/204
5. Original due Date: September 22, 2002	<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached	(1 mo) (2 mos) (3 mos) (4 mos) (5 mos)	\$110/\$55 = \$400/\$200 = \$920/\$460 = \$1,440/\$720 = \$1,960/\$980 =	+ \$200			115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract			- \$0			
8.			Extension Fee	+ \$200		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee .....		+ \$110/\$55	+ \$0			148/248
10. If IDS attached requires Official Fee under Rule 97 (c), .....	add	+ \$180				126
or if Rule 97(d) Request .....	add	+ \$180	+ \$0			126
11. After-Final Request Fee per rules 129(a) and 17(r) .....		+ \$740/370	+ \$0			146/246
12. No. of additional inventions for examination per Rule 129(b) .....		x \$740/370 ea	+ \$0			149/249
13. Request for Continued Examination (RCE) .....		+ \$740/370	+ \$0			1179/1279
14. Petition fee for .....			+ \$0			
15.			TOTAL FEE =	\$200		

16. \*If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. \*\*If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. \*\*\*If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

PLEASE CHARGE  
OUR DEP. ACCT

11/22/2002 NMOHAMM1 00000150 033975 09762594 ✓

Our Deposit Account No. 03-3975)

(Our Order No. 076934 0277848

C# M#

01 FC:2252 200.00 CH

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP  
Intellectual Property Group

By Atty: Robin L. Teskin

Sig: 

P.O. Box 10500  
McLean, VA 22102  
Tel: (703) 905-2000

Atty/Sec: RLT/af

Reg. No. 35,030

Fax: (703) 905-2500  
Tel: (703) 905-2200

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments